A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy

Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ovarian cancers that have impaired homologous recombination (HR) ability and improved sensitivity to PARP inhibitor. However, a substantial subset of BRCA-mutant ovarian cancer patients shows less impaired or unimpaired HR...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shaojun, Yuan, Yuan, Hao, Dapeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249855/
https://www.ncbi.nlm.nih.gov/pubmed/25437005
http://dx.doi.org/10.1371/journal.pone.0113169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249855/
https://www.ncbi.nlm.nih.gov/pubmed/25437005
http://dx.doi.org/10.1371/journal.pone.0113169

Ejemplares similares